Corden Pharma expands capacity, staff in Boulder
BOULDER — Corden Pharma is expanding its capabilities to manufacture active pharmaceutical ingredients at the east Boulder plant it acquired in 2011 from Roche Colorado Corp.
The expansion will allow the company to increase its production of oligonucleotides, which are chemically synthesized short nucleic acid polymers that are designed to fuse with DNA or ribonucleic acid sequences. They’re used to treat some cancers as well as infectious and genetic diseases.
The expansion at the plant at 2075 55th St., which was completed in the first quarter of this year, amounted to “renovation of existing space…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!



